Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Rheumatology
•
Hematology
•
Pediatric Hematology
•
Lupus nephritis
•
Antiphospholipid Syndrome
•
Nephrology
•
Glomerulonephritis
•
Anticoagulation
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
Related Questions
Do you avoid ESA use in patients with anemia and chronic kidney disease who also have APLS and risk for thrombosis?
How do you approach discussing the pill burden of voclosporin with patients who already have to take a regimen such as MMF+HCQ+ACEi and possibly more?
How do you determine duration of therapy for patients who have responded well to voclosporin therapy?
How would you approach post-operative VTE prophylaxis for renal transplant in patients with a prior history of provoked VTE?
What drives you to choose voclospsorin over tacrolimus given the substantially higher cost?
Do you ever combine voclosporin and belimumab in the treatment of lupus nephritis?
Would you treat a patient aggressively for lupus nephritis if they have persistent proteinuria over 1 gram but cannot get a timely kidney biopsy?
How do you manage arthritis resulting from deferiprone in transfusion dependent thalassemia?
How would you approach management of a patient with ESRD on the transplant list who is found to have high titer APS labs (ACL, B2GP1, LAC)?
How would you manage a patient with SLE that has a remote history of positive anti-phospholipid antibodies with a current DVT and now completely negative APLs?
